Unknown

Dataset Information

0

Hybrid cytokine IL233 renders protection in murine acute graft vs host disease (aGVHD).

ABSTRACT: Previously, we generated IL233, a hybrid cytokine composed of interleukin (IL)-2 and IL-33, with better therapeutic potential than either cytokine in multiple inflammatory diseases, in part through promoting T-regulatory cells (Tregs). Here we test the potential of IL233 pretreatment in a murine model of excessive Th1 activation, the parent-into-F1 model of acute GVHD (aGVHD). Five days of IL233 pretreatment of the recipients blocked or delayed the aGVHD-linked loss of B cells as seen in either the peripheral blood (day-11) or lymph nodes (day-14). IL233 pretreatment also prevented the expansion of donor CD8 T-cells in blood and LN at day-14 and significantly reduced day-14 serum IFNγ and TNFα compared to saline treated GVHD mice although, the level of Tregs did not statistically differ between saline and IL233-treated mice. Overall, the current study provides support for the use of IL233 as a therapeutic option in excessive Th1/CD8-driven conditions.

SUBMITTER: Venkatadri R 

PROVIDER: S-EPMC8128039 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Hybrid cytokine IL233 renders protection in murine acute graft vs host disease (aGVHD).

Venkatadri Rajkumar R   Sabapathy Vikram V   Dogan Murat M   Sharma Rohan R   Mohammad Saleh S   Via Charles S CS   Sharma Rahul R  

Cellular immunology 20210323

Previously, we generated IL233, a hybrid cytokine composed of interleukin (IL)-2 and IL-33, with better therapeutic potential than either cytokine in multiple inflammatory diseases, in part through promoting T-regulatory cells (Tregs). Here we test the potential of IL233 pretreatment in a murine model of excessive Th1 activation, the parent-into-F1 model of acute GVHD (aGVHD). Five days of IL233 pretreatment of the recipients blocked or delayed the aGVHD-linked loss of B cells as seen in either  ...[more]

Similar Datasets

Transcriptomics FRCs promote Treg function in acute graft-versus-host disease (aGvHD)
2021-03-03 | GSE168114 | GEO
Unknown IL-17C Mitigates Murine Acute Graft-vs.-Host Disease by Promoting Intestinal Barrier Functions and Treg Differentiation.
| S-EPMC6275224 | biostudies-literature
Unknown The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease.
| S-EPMC6518430 | biostudies-literature
Proteomics Plasma in patients with acute myeloid leukemia (AML) with acute graft versus host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation vs Plasma in patients with AML without aGVHD
2022-06-11 | GSE205842 | GEO
Unknown Compound A Increases Cell Infiltration in Target Organs of Acute Graft-versus-Host Disease (aGVHD) in a Mouse Model.
| S-EPMC8303851 | biostudies-literature
Unknown Achievement of Tolerance Induction to Prevent Acute Graft-vs.-Host Disease.
| S-EPMC6419712 | biostudies-literature
Unknown Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses.
| S-EPMC9536261 | biostudies-literature
Unknown IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects.
| S-EPMC4391991 | biostudies-literature
Transcriptomics Transcription profiling of human leukocytes from peripheral blood stem cell transplant patients to investigate acute graft versus host disease aGVHD
2008-06-15 | E-GEOD-7510 | biostudies-arrayexpress
Unknown A T-Cell Surface Marker Panel Predicts Murine Acute Graft-Versus-Host Disease.
| S-EPMC7880247 | biostudies-literature